HomeCompareLABP vs EPRT

LABP vs EPRT: Dividend Comparison 2026

LABP yields 8.72% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $27.8K in total portfolio value· pulled ahead in Year 6
10 years
LABP
LABP
● Live price
8.72%
Share price
$22.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,512.64
Full LABP calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — LABP vs EPRT

📍 EPRT pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLABPEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LABP + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LABP pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LABP
Annual income on $10K today (after 15% tax)
$741.39/yr
After 10yr DRIP, annual income (after tax)
$1,285.74/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,628.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LABP + EPRT for your $10,000?

LABP: 50%EPRT: 50%
100% EPRT50/50100% LABP
Portfolio after 10yr
$49.5K
Annual income
$7,176.68/yr
Blended yield
14.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

LABP
Analyst Ratings
2
Buy
4
Hold
1
Sell
Consensus: Hold
Altman Z
-3.1
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LABP buys
0
EPRT buys
0
No recent congressional trades found for LABP or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLABPEPRT
Forward yield8.72%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$35.6K$63.4K
Annual income after 10y$1,512.64$12,840.73
Total dividends collected$11.9K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: LABP vs EPRT ($10,000, DRIP)

YearLABP PortfolioLABP Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,572$872.22$11,205$505.18+$367.00LABP
2$13,326$943.32$12,672$682.46+$654.00LABP
3$15,274$1,015.18$14,490$930.48+$784.00LABP
4$17,430$1,087.46$16,786$1,282.69+$644.00LABP
5$19,810$1,159.83$19,753$1,791.56+$57.00LABP
6← crossover$22,429$1,231.95$23,677$2,541.64$1.2KEPRT
7$25,302$1,303.55$29,008$3,672.99$3.7KEPRT
8$28,448$1,374.36$36,463$5,425.08$8.0KEPRT
9$31,883$1,444.13$47,238$8,221.57$15.4KEPRT
10$35,628$1,512.64$63,385$12,840.73$27.8KEPRT

LABP vs EPRT: Complete Analysis 2026

LABPStock

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Full LABP Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this LABP vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LABP vs SCHDLABP vs JEPILABP vs OLABP vs KOLABP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.